Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of EXG-5003
NCT04863131Phase 2Completed
- Sponsor
- Fujita Health University
- Start
- Apr 2021
- Primary completion
- Dec 2022
- Modality
- mRNA Vaccines, RNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of EXG-5003 in coronavirus disease 2019 (COVID-19), sponsored by Fujita Health University. Started Apr 2021; status: completed.
02
Drugs
EXG-5003
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04863131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04863131.